[Evaluation of clinical tolerability and diagnostic efficacy of ioversol 350 in UIV. A randomized double-blind study of ioversol 350 versus iohexol 350].
The authors evaluated the clinical safety and the efficacy of ioversol compared to the reference contrast medium iohexol, during IVP. The clinical safety has been evaluated by the occurrence of side-effects. The efficacy was appreciated in terms of insufficient, medium, good or excellent. No side-effect was recorded for both contrast media. There was no difference in opacification quality and efficacy between ioversol and iohexol. The authors conclude that ioversol is a safe and effective contrast medium which can be, therefore, particularly recommended for urographic examinations of high risk patients.
Voegeli
E
E
Département de Radiologie, Hôpital Cantonal, Lucerne, Suisse.
Woessmer
B
B
D004311:Double-Blind Method; D005260:Female; D006417:Hematuria / Q000000981:diagnostic imaging; D006801:Humans; D007275:Injections, Intravenous; D007472:Iohexol / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011469:Prostatic Diseases / Q000000981:diagnostic imaging; D014283:Triiodobenzoic Acids / Q000008:administration & dosage / Q000009:adverse effects; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging; D014552:Urinary Tract Infections / Q000000981:diagnostic imaging; D014567:Urography / Q000379:methods*
D014283:Triiodobenzoic Acids; D007472:Iohexol; C054871:ioversol
Evaluation de la tolérance clinique et de l'efficacité diagnostique du ioversol 350 en UIV. Etude randomisée en double aveugle ioversol 350 versus iohexol 350.